Literature DB >> 12675032

Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Jonathan C Song1, Peter J McDonnell, Erlinda M Gordon, Frederick L Hall, W French Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12675032

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  2 in total

Review 1.  Convergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked Retinoschisis.

Authors:  Ronald A Bush; Lisa L Wei; Paul A Sieving
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-22       Impact factor: 6.915

2.  Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Authors:  Erlinda M Gordon; Joshua R Ravicz; Seiya Liu; Sant P Chawla; Frederick L Hall
Journal:  Mol Clin Oncol       Date:  2018-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.